News

Meitheal Pharmaceuticals Announces Findings from Collaborative Research Study with Premier Inc. Evaluating Anticoagulant Treatment of COVID-19 Patients

Data Support Conditional Recommendation of Prophylactic Dosage of Anticoagulants for Preventing Blood Clots in Patients with COVID-19, Reinforcing American Society of Hematology (ASH) 2021 Guidelines 

Findings Suggest that Differences in Outcomes by Treatment Dosage Not Due to Patient Age

 

Chicago, IL., September 15, 2021 – Meitheal Pharmaceuticals, Inc., a fully integrated generic injectables company based in Chicago, Illinois, today announced findings from a research collaboration with Premier Applied Sciences (PAS), the research and analytics division of Premier Inc., evaluating anticoagulant treatment on outcomes of hospitalized patients diagnosed with COVID-19. Anticoagulants are medications that prevent blood clots. Research has shown that patients with COVID-19 are more prone to developing blood clots during the course of their illness. [1] 

Researchers found that patients on a prophylactic dose of the anticoagulants enoxaparin or heparin have shorter hospital stays, lower cost, and better clinical outcomes compared to patients on a therapeutic dose.[2] Moreover, when the therapeutic group is split by age, lab values suggest that younger patients are just as sick as the older group, without improved outcomes.[3] 

These findings support American Society of Hematology (ASH) 2021 guidelines[4] conditionally recommending prophylactic dosage of anticoagulants for thromboprophylaxis in patients with COVID-19 and suggest that differences in outcomes by treatment dosage are not due to patient age. The research project was presented at the Premier Breakthroughs Conference in July and the fully detailed results will be published later this year. 

“We are proud to partner with Premier to identify COVID-19 treatment options that offer better patient outcomes,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals. “At Meitheal, we continuously work towards bridging important gaps in healthcare with an affordable and diversified range of generic injectables, and by assessing the effects of anticoagulant treatment on patient outcomes, we can help to improve care for COVID-19 patients.” 

“Premier’s Healthcare database will continue to provide life sciences partners like Meitheal the opportunity to use real-world data to conduct evidence-based studies of drugs and clinical outcomes in an effort to improve the overall quality, safety and cost-effectiveness of care,” said Denise Juliano, Group Vice President of Life Sciences at Premier.

The primary objective of the study was to describe and compare the clinical outcomes and usage of resources of hospitalized patients diagnosed with COVID-19 and to assess the effects of anticoagulant treatment on outcomes. Secondary objectives of the study included a description and comparison of demographic, visit, hospital, and clinical characteristics between exposure groups. Data from a Special Release of the Premier Healthcare database (PHD-SR)[5] was used to support all objectives.[6]                                        

 

ABOUT MEITHEAL PHARMACEUTICALS

 

Since 2017, Meitheal Pharmaceuticals has bridged critical gaps in the US healthcare market by supplying high quality, affordable generic injectables. Our diversified product range — from antibiotics, anticoagulants, and muscle relaxants to drugs used in chemotherapy — represents practical solutions for countless patients around the country, as well as Meitheal’s commitment to their care. Based in Chicago, Illinois, our aim each day is producing quality and ensuring affordability, using the traditional Irish guiding principle we are named for — Meitheal (Mee·hall): working together toward a common goal, for the greater good.

 

Learn more about who we are and what we do at www.meithealpharma.com.

 

MEDIA CONTACT

Meitheal Pharmaceuticals, Inc.

Thomas Shea, CEO

224 443 4522

info@meithealpharma.com


____________________________________________________________________________________________________________________________________________________

[1] Carfora V, Spiniello G, et al. Anticoagulant treatment in COVID 19: a narrative review. Journal of Thrombosis and Thrombolysis. 2020; https://doi.org/10.1007/s11239-020-02242-0

[2] Robinson, K. (2021, September 9). Studying the Effect of Anticoagulant Use in COVID-19 Patients. Vimeo. Retrieved September 13, 2021, from https://vimeo.com/569930905/461b2d74d9.

[3] Premier Inc. (2021, September 12). Data delivered: Collaborating with pharma to study anticoagulant use... Premier. Retrieved September 13, 2021, from https://www.premierinc.com/newsroom/blog/data-delivered-partnering-with-pharma-on-anticoagulant-use-in-covid-19-patients.

[4] Cuker, A., Tseng, et al. (2021). American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Advances, 5(3), 872–888. https://doi.org/10.1182/bloodadvances.2020003763 

[5] The PHD-SR contains real-world data representing more than 2.1 million patient encounters with a positive COVID-19 diagnosis.

[6] Meitheal selected the PHD-SR as the data source for its retrospective cohort study on the effect of anticoagulant use in COVID-19 patients discharged from U.S. hospitals between April 1, 2020 and November 30, 2020.